Elucid has raised $55 million in an oversubscribed Series D financing, bringing total funding for the AI-powered cardiovascular imaging company to approximately $185 million.
The round includes a new investment from an unidentified large medical technology company, becoming Elucid’s fourth publicly traded strategic investor.
Other new and existing investors include IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital.
Elucid plans to use the financing to accelerate commercialization of its cardiovascular imaging platform, including Plaque-IQ and BioIntegrated FFR-CT, while supporting additional AI research and clinical studies.
The company’s FFR-CT 510(k) submission is currently under FDA review.
Plaque-IQ is already FDA cleared and is designed to quantify high-risk plaque types and plaque composition in coronary and carotid arteries using non-invasive imaging.
Elucid is developing an integrated platform combining plaque biology, vessel anatomy and FFR physiology to help clinicians assess cardiovascular risk and personalize treatment strategies.
KEY QUOTE:
“Analogous to oncology’s shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalized treatment to coronary artery disease management. Physician feedback indicating that our current platform can uniquely lead to better care decisions fuels our mission to predict and personalize the prevention of heart attacks and strokes.”
Kelly Huang, Ph.D., Chief Executive Officer of Elucid
